Lumos Diagnostics Holdings Limited (ASX:LDX)

Market Cap	97.01M +398.5%
Revenue (ttm)	18.31M -16.7%
Net Income	-13.88M
EPS	-0.02
Shares Out	923.87M
PE Ratio	n/a
Forward PE	0.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	905,407
Open	0.1050
Previous Close	0.1050
Day's Range	0.1000 - 0.1100
52-Week Range	0.0260 - 0.3300
Beta	0.54
Analysts	n/a
Price Target	n/a
Earnings Date	May 27, 2026

About ASX:LDX

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platfor...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: LDX

Financial Performance

In fiscal year 2025, ASX:LDX's revenue was $12.40 million, an increase of 11.40% compared to the previous year's $11.13 million. Losses were -$7.18 million, -16.40% less than in 2024.

Financial numbers in USD